30% rule! Risk of RA development in Pre clinical RA patient in the next 3 to 5 years . Kevin Deane #RNL2023 ⁦@RheumNow⁩ https://t.co/J6Polz70im

Dr Philip Conaghan at #RNL2023 X-rays are misleading in OA OA is a CLINICAL disease Radiographs do not help in diagnosis or monitoring ⁦@RheumNow⁩ https://t.co/ZrAfPN02qi

#RNL2023 @RheumNow There are a lot of RA Rx on market now - do we need more? Dr. Brenner: YES Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/zJRRisGW9i

@RheumNow Live #RNL2023 Stanley Cohen, MD: Use of JAK inhibitor in patients with known ASCVD: Number needed to harm 16 ASCVD is biggest risk factor for MACE events with JAKi https://t.co/gXNUOO8seG

Dr Brenner at #RNL2023 Excellent description on how fibroblasts are major producers of IL-6 producers Clinically presents a target for blocking the fibroblasts, upstream the inflammatory cascade in RA @RheumNow https://t.co/TserFZtvhV

JAKinib safety takeaways - avoid in older population > 65 yo, malignancy, CV risk, VTE risk - appropriate in younger pts without VTE/CVD risk factors #RNL2023 @RheumNow https://t.co/5i1bRqqr7g

@RheumNow Live 2023 Starts Tomorrow! Or does it start earlier? Love that there is a pre-learn and pre-test to set the stage for #RNL2023 Excited for this talk by @anisha_dua on assessment for GCA/PMR #RheumTwitter https://t.co/VcawlnaPFf

Faith and Miracle Larry This week on the podcast, Dr. Jack Cush recalls what life was like early on during COVID, from March to June of 2020. https://t.co/SfidfBF1En https://t.co/Jnv6moxYwQ

• https://bit.ly/3yLqLyX

#RNL2023 @RheumNow Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/AZDKShOPbU

Dr. Deanne reminds us that RA is worth preventing for many reasons. #RNL2023 @RheumNow https://t.co/va0RmdhUQR

Dr. Kevin Deane on preclinical-RA Very complex history on development of RA with multiple phases before detectable RA shows up in your clinic. #RNL2023 @RheumNow https://t.co/vzQFhik0aK

#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years @RheumNow https://t.co/skp1K4r1hF

STOP-RA study on HCQ preventing RA... HCQ did NOT prevent RA development in pre-RA pts @RheumNow #RNL2023 https://t.co/Vv3szkqxWh

#RNL2023 @RheumNow Kevin Deane presents his STOP RA Trial HCQ is safe and easy - can you use it in pre-clinical RA to prevent disease? NO EVIDENCE of decreased progression of RA in HCQ compared to placebo https://t.co/1OSVubd9rO

Treatment with MTX in early CCP+ RA thought to be effective in slowing disease however StopRA study did not show a difference between HCQ and PBO in patients. We need to know more about HCQ vs MTX in this space! #RNL2023 @RheumNow https://t.co/7asmvVfXiC